We are part of the CSL Limited group of companies. See how we're Driven by Our Promise.
We collaborate with rare disease organizations to promote quality medical care and services.
We offer a variety of support programs and activities for the patients we serve.
We also aim to make sure that nothing holds you back from getting the therapies you need.
We work every day as if someone’s life depends on it, because it does.
We manufacture products to treat a number of rare diseases.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL Behring.
2017
The two companies have entered into a strategic collaboration and purchase option agreement to expedite the development of cl…
Hizentra PATH study, the largest controlled clinical study in patients with CIDP, met its primary endpoint
A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE…
- HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US - Oral presentation will highligh…
There are more than 350,000 cardiac arrests annually in the U.S.; nearly 90 percent are fatal but when CPR is administered im…
CSL Behring’s LEAD grant is helping them advocate more effectively in a shifting health care environment.
AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat hemophilia A
CSL Behring commits $4.92 million to Penn State's multidisciplinary Center of Excellence in Biotechnology
Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Ini…
2019
2018
Popular search terms:
Americas
Asia Pacific
Middle East
Europe
